FRANCE; UNITED STATES OF AMERICA —Paris-headquartered software provider Biolevate has completed a €30 million Series A financing round co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F and existing backer EQT Ventures. The capital injection will support the deployment of the company's enterprise automation platform across international markets and facilitate its expansion into North America with a new office in Boston. Founded by former Dataiku engineers and artificial intelligence researchers, Biolevate develops evidence-grounded AI systems designed to automate complex, highly regulated operational workflows for pharmaceutical companies and research institutions.
The investment highlights a major shift in how the global life sciences sector approaches operational efficiency amid strict regulatory frameworks. As pharmaceutical companies face pressure to accelerate drug development timelines and streamline regulatory approvals, general-purpose generative tools often fall short due to stringency around auditability and data verification. Biolevate addresses this challenge by providing domain-specific software agents that tie outputs directly to verifiable source documentation, allowing deployment in high-compliance environments across research, clinical trials, and regulatory intelligence.
From a market perspective, the transaction signals rising venture appetite for specialized enterprise platforms that bring vertical AI into life sciences operations. By scaling its workforce and expanding into the Boston biotechnology corridor, Biolevate aims to capture market share among top-tier pharmaceutical manufacturers and regulatory entities. The expansion reflects a wider industry trend toward adopting automated, auditable decision-support tools capable of mitigating commercial bottlenecks and expediting time-to-market for complex therapies.
